<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895505</url>
  </required_header>
  <id_info>
    <org_study_id>DDOAT2006</org_study_id>
    <nct_id>NCT00895505</nct_id>
  </id_info>
  <brief_title>D-Dimer Guided Oral Anticoagulant Treatment (OAT)</brief_title>
  <acronym>DDOAT2006</acronym>
  <official_title>Safety and Efficacy of a D-Dimer-Guided Strategy for Extension of Secondary Prophylaxis of Venous Thromboembolism - a Prospective and Randomized Management Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will investigate the hypothesis that D-Dimer testing can be successfully
      used to tailor the duration of OAT in patients after an unprovoked episode of deep venous
      thrombosis (DVT) using a prospective, randomized, and controlled design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After a first episode of acute deep venous thrombosis (DVT) the risk of recurrence is
      relatively high and clinical consequences are important. Therefore, secondary prophylaxis
      using oral anticoagulant treatment (OAT) is usually established in these patients. This
      treatment very effectively reduces the risk of recurrences but induces an increased risk of
      bleeding. Major bleeding complications can be expected in ~2% patient-years. Therefore,
      current recommendations limit OAT to a period of 3 to 12 months. After stopping of OAT,
      however, ~10 % of patients with an initial episode of unprovoked DVT will develop a recurrent
      event within 1 year. This group of patients may benefit from prolonged OAT. The results of 2
      independent observational studies showed a significantly higher risk of recurrence in
      patients showing increased levels of D-Dimer after withdrawal of OAT. D-Dimer is a biomarker
      that indicates fibrin formation followed by fibrinolysis. Based on these data we hypothesize
      that D-Dimer testing can be successfully used to tailor the duration of OAT in patients after
      an unprovoked episode of DVT. This clinical trial will investigate this hypothesis using a
      prospective, randomized, and controlled design.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of objectively documented deep vein thrombosis (DVT) and/or pulmonary embolism (PE)</measure>
    <time_frame>Duration of intervention per patient (24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of signs and symptoms associated with OAT-induced bleeding measured using the World Health Organization (WHO) bleeding scale.</measure>
    <time_frame>Duration of intervention per patient (24 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Deep Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>oral anticoagulants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Experimental intervention: Extension of OAT in VTE patients showing high plasma levels of D-Dimer after end of routine secondary prophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control: Withdrawal of OAT in VTE patients after end of routine secondary prophylaxis and receiving low molecular weight heparin in risk situations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenprocoumon</intervention_name>
    <description>Phenprocoumon 3 mg, tablet, INR adjusted</description>
    <arm_group_label>oral anticoagulants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin-Natrium</intervention_name>
    <description>Warfarin-Natrium 5 mg, tablet, INR adjusted</description>
    <arm_group_label>oral anticoagulants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be enrolled in this study, patients must:

          -  have an objectively confirmed first episode of unprovoked VTE or of VTE during a minor
             transient risk factor. Minor transient risk factors include 6 weeks of estrogen
             therapy, prolonged air travel (i.e., &gt; 6 hours), pregnancy, less marked leg injuries
             or immobilization without injury or surgical intervention

          -  be scheduled to receive oral anticoagulant treatment for at least 3 months

          -  be willing to be randomized

          -  be willing to participate for the full duration of the study

        Exclusion Criteria:

          -  pregnancy or breast feeding

          -  contraindications against OAT (i.e., intracranial hemorrhage, subarachnoid hemorrhage,
             hemorrhagic stroke)

          -  age &lt; 18 years

          -  presence of antiphospholipid antibodies or any other thrombophilic risk factor
             requiring long-term OAT (i.e., antithrombin deficiency, hereditary PC deficiency)

          -  poor patient compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Poetzsch, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernd Poetzsch, Professor</last_name>
    <phone>+49-228-28716745</phone>
    <email>bernd.poetzsch@ukb.uni-bonn.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Poetzsch, Professor</last_name>
      <email>bernd.poetzsch@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Bernd Poetzsch, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <last_update_submitted>May 7, 2009</last_update_submitted>
  <last_update_submitted_qc>May 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Bernd Pötzsch</name_title>
    <organization>Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn</organization>
  </responsible_party>
  <keyword>DVT</keyword>
  <keyword>Venous thromboembolism</keyword>
  <keyword>D-Dimer</keyword>
  <keyword>thrombophilia</keyword>
  <keyword>secondary prophylaxis</keyword>
  <keyword>secondary prophylaxis using oral anticoagulant treatment (OAT)</keyword>
  <keyword>higher risk of recurrence in patients showing increased levels</keyword>
  <keyword>of D-Dimer after withdrawal of OAT</keyword>
  <keyword>D-Dimer-based treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Phenprocoumon</mesh_term>
    <mesh_term>Fibrin fragment D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

